Skip to content

HPV Integration and Tumorigenesis of Uterine Cervical Adenocarcinoma

A Multi-omics Study on the Human Papillomavirus Integration and Tumorigenesis of Uterine Cervical Adenocarcinoma

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03742869
Enrollment
40
Registered
2018-11-15
Start date
2018-11-10
Completion date
2021-11-23
Last updated
2018-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Adenocarcinoma, Genome-wide Association Study, Human Papillomavirus, Metabolome, Prognosis, Transcriptome, Tumorigenesis, Whole Exome Sequencing

Brief summary

This study aims to analyze the multi-omics results between uterine cervical adenocarcinoma patients with and without human papillomavirus (HPV) infections. The multi-omics profiles include genome wide association study (GWAS), whole exome sequencing, analysis of transcriptomics and metabolomics. The HPV integration status is interpreted by GWAS. A comprehensive multi-omics will reveal the role of HPV integration in the molecular mechanism of tumorigenesis and prognosis of uterine cervical adenocarcinoma.

Interventions

COMBINATION_PRODUCTA multi-omics analysis

A multi-omics analysis including genome-wide association study, whole exome sequencing, transcriptomics and metabolomics.

Sponsors

Lei Li
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

* Confirmed primary adenocarcinoma of the uterine cervix * Signed an approved informed consents * Feasible for biopsy

Exclusion criteria

* Not meeting all of the inclusion criteria

Design outcomes

Primary

MeasureTime frameDescription
Frequencies of somatic driving mutationsTwo yearsThe differences of frequencies of somatic driving mutations will be compared between patients with and without HPV integration.

Secondary

MeasureTime frameDescription
Frequencies of alteration of RNA expressionTwo yearsThe alteration of patterns of RNA expression, including mRNA, miRNA, and lncRNA, will be compared between patients with and without HPV integration.
Frequencies of alteration of protein expression and signal pathwayTwo yearsThe alteration of patterns of protein expression and signal pathway will be compared between patients with and without HPV integration.
Progression-free survivalFive yearsProgression-free survival between patients with differential expressed multi-omics will be compared.

Countries

China

Contacts

Primary ContactLei Li, M.D.
lileigh@163.com13911988831

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026